Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Jenna M. Shaxted"'
Publikováno v:
STAR Protocols, Vol 3, Iss 2, Pp 101407- (2022)
Summary: High-content imaging of tumor organoids (TOs) treated with therapeutic agents provides detailed cell viability readouts at the organoid level. In contrast, most used protocols provide one number per well. While requiring the use of inverted
Externí odkaz:
https://doaj.org/article/5b2d4adf4c1447ae96ad49af3a0b1317
Autor:
Brian M. Larsen, Madhavi Kannan, Lee F. Langer, Benjamin D. Leibowitz, Aicha Bentaieb, Andrea Cancino, Igor Dolgalev, Bridgette E. Drummond, Jonathan R. Dry, Chi-Sing Ho, Gaurav Khullar, Benjamin A. Krantz, Brandon Mapes, Kelly E. McKinnon, Jessica Metti, Jason F. Perera, Tim A. Rand, Veronica Sanchez-Freire, Jenna M. Shaxted, Michelle M. Stein, Michael A. Streit, Yi-Hung Carol Tan, Yilin Zhang, Ende Zhao, Jagadish Venkataraman, Martin C. Stumpe, Jeffrey A. Borgia, Ashiq Masood, Daniel V.T. Catenacci, Jeremy V. Mathews, Demirkan B. Gursel, Jian-Jun Wei, Theodore H. Welling, Diane M. Simeone, Kevin P. White, Aly A. Khan, Catherine Igartua, Ameen A. Salahudeen
Publikováno v:
Cell Reports, Vol 36, Iss 4, Pp 109429- (2021)
Summary: Patient-derived tumor organoids (TOs) are emerging as high-fidelity models to study cancer biology and develop novel precision medicine therapeutics. However, utilizing TOs for systems-biology-based approaches has been limited by a lack of s
Externí odkaz:
https://doaj.org/article/9e05120e2cf8481abf4978520140395c
Autor:
Jagadish Venkataraman, Chi Sing Ho, Jenna M. Shaxted, Madhavi Kannan, Brian M. Larsen, Brandon Mapes, Ameen A. Salahudeen, Sonal Khare
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundCell engager and adoptive cell therapeutics have emerged as efficacious and durable treatments in patients with B-cell malignancies. Though many analogous strategies are under development in solid tumors, none have received approval. Precli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be1e6e8ba4a3b13c712f82b6a7717da8
https://doaj.org/article/f1765113dc9a4f438612b0652632246f
https://doaj.org/article/f1765113dc9a4f438612b0652632246f
Autor:
Theodore H. Welling, Diane M. Simeone, Benjamin A. Krantz, Aïcha BenTaieb, Andrea Cancino, Chi Sing Ho, Jeffrey A. Borgia, Jeremy V. Mathews, Brandon Mapes, Michael A. Streit, Jian Jun Wei, Ameen A. Salahudeen, Bridgette E. Drummond, Veronica Sanchez-Freire, Martin C. Stumpe, Aly A. Khan, Tim A. Rand, Ende Zhao, Kelly E. McKinnon, Benjamin D. Leibowitz, Demirkan B. Gursel, Madhavi Kannan, Jagadish Venkataraman, Yi-Hung Carol Tan, Brian M. Larsen, Jonathan R. Dry, Gaurav Khullar, Jenna M. Shaxted, Catherine Igartua, Kevin P. White, Daniel V.T. Catenacci, Ashiq Masood, Jason Perera, Jessica Metti, Michelle M. Stein, Igor Dolgalev, Lee F. Langer, Yilin Zhang
Publikováno v:
Cell Reports, Vol 36, Iss 4, Pp 109429-(2021)
Summary: Patient-derived tumor organoids (TOs) are emerging as high-fidelity models to study cancer biology and develop novel precision medicine therapeutics. However, utilizing TOs for systems-biology-based approaches has been limited by a lack of s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85ee6070df11c2b91a956a81ab264980
https://pubmed.ncbi.nlm.nih.gov/34320344
https://pubmed.ncbi.nlm.nih.gov/34320344